Skip to content

Common Stock at other companies

Amgen logo
AmgenAMGN
2.8B0.0%
Janux Therapeutics logo
Janux TherapeuticsJANX
$60K+1.7%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
400M0.0%
Vor Biopharma logo
Vor BiopharmaVOR
$19K+46.2%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$6K0.0%
Immunome logo
ImmunomeIMNM
$11K+22.2%

Other financials

Income statement

See full
Revenue$10.3M-79.9%
Operating income-$19.7M-187%
Net income-$18.2M-178%
EPS (diluted)-$0.10-137%

Balance sheet

See full
Cash & equivalents$28.8M-39.4%
Total debt$2.9M-65.0%
Total equity$319.9M+1,177%
Total assets$359.4M+265%

Cash flow

See full
Operating cash flow-$25.5M-21.4%
CapEx--100%
Free cash flow-$25.5M-20.7%

Valuation

See full
Market cap$711.89M+94.8%
Enterprise value$685.92M+110%
P/S20×+17.6×

Profitability

See full
Operating margin-181.9%-206pp
Net margin-166.4%-195pp
FCF margin-225.6%-334pp

Returns & leverage

See full
Return on equity-34.3%
Debt / equity-0.3×
Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CytomX Therapeutics's common stock?
CytomX Therapeutics (CTMX) reported common stock of $2K in Q1 2026.
How has CytomX Therapeutics's common stock changed year-over-year?
CytomX Therapeutics's common stock increased by 100.0% year-over-year, from $1K to $2K.
What is the long-term trend for CytomX Therapeutics's common stock?
Over 5 years (2020 to 2025), CytomX Therapeutics's common stock has grown at a 14.9% compound annual growth rate (CAGR), from $1K to $2K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).